Stanley Laman Group Ltd. Has $5.34 Million Position in Neurocrine Biosciences, Inc. $NBIX

Stanley Laman Group Ltd. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 30.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 42,521 shares of the company’s stock after purchasing an additional 9,862 shares during the period. Stanley Laman Group Ltd.’s holdings in Neurocrine Biosciences were worth $5,344,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Dodge & Cox boosted its holdings in shares of Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock valued at $612,129,000 after buying an additional 2,518,199 shares during the period. Wellington Management Group LLP lifted its position in Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after acquiring an additional 640,556 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Neurocrine Biosciences by 3.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock worth $170,281,000 after purchasing an additional 49,088 shares during the period. Braidwell LP increased its holdings in Neurocrine Biosciences by 32.2% during the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock worth $131,827,000 after purchasing an additional 290,135 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Neurocrine Biosciences by 8.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,159,367 shares of the company’s stock valued at $128,226,000 after purchasing an additional 89,271 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Up 1.9%

NASDAQ NBIX opened at $140.09 on Friday. The firm has a market capitalization of $13.89 billion, a P/E ratio of 41.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.21. The firm’s fifty day moving average price is $138.65 and its two-hundred day moving average price is $125.96. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.08. The business had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. Neurocrine Biosciences’s revenue was up 16.5% on a year-over-year basis. During the same period last year, the business posted $1.63 EPS. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 106,322 shares of the business’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the transaction, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. The trade was a 17.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the subject of several recent research reports. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research report on Thursday, July 10th. They set a “buy” rating and a $182.00 price target for the company. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Needham & Company LLC boosted their price objective on shares of Neurocrine Biosciences from $161.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, September 22nd. Finally, Truist Financial started coverage on shares of Neurocrine Biosciences in a research report on Monday, July 21st. They issued a “buy” rating and a $163.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.44.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.